UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Newspaper Article (70989) 70989
Journal Article (13242) 13242
Web Resource (1659) 1659
Trade Publication Article (810) 810
Transcript (611) 611
Magazine Article (556) 556
Report (218) 218
Government Document (63) 63
Book Chapter (28) 28
Streaming Video (16) 16
Book Review (10) 10
Conference Proceeding (5) 5
Publication (5) 5
Newsletter (4) 4
Book / eBook (3) 3
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
covid-19 (86862) 86862
coronaviruses (67603) 67603
pandemics (28984) 28984
clinical trials (18352) 18352
severe acute respiratory syndrome coronavirus 2 (17624) 17624
stockholders (17588) 17588
earnings per share (17337) 17337
patients (12974) 12974
net losses (12357) 12357
vaccines (12129) 12129
medical research (10957) 10957
biotechnology industry (10607) 10607
fda approval (9595) 9595
pharmaceutical industry (9420) 9420
humans (9358) 9358
archives & records (9298) 9298
science & technology (9060) 9060
life sciences & biomedicine (8586) 8586
research & development--r&d (7715) 7715
sars-cov-2 (7567) 7567
web sites (7423) 7423
collaboration (7084) 7084
webcasting (6920) 6920
investments (6836) 6836
drug dosages (6525) 6525
infections (6356) 6356
chief executive officers (6209) 6209
corporate profiles (5666) 5666
antibodies (5634) 5634
hospitals (5602) 5602
disease transmission (5357) 5357
cancer therapies (4766) 4766
disease (4651) 4651
regulatory approval (4498) 4498
infectious diseases (4129) 4129
product development (4097) 4097
oncology (3974) 3974
public health (3950) 3950
stock exchanges (3948) 3948
cancer (3919) 3919
viruses (3905) 3905
manufacturing (3854) 3854
mortality (3633) 3633
researchers (3632) 3632
laboratories (3523) 3523
corporate profits (3493) 3493
pharmaceuticals (3460) 3460
agreements (3374) 3374
presidents (3314) 3314
drugs (3288) 3288
proteins (3146) 3146
epidemics (2955) 2955
male (2922) 2922
cytokines (2898) 2898
betacoronavirus (2884) 2884
medicine (2877) 2877
female (2869) 2869
immunotherapy (2684) 2684
covid-19 diagnostic tests (2615) 2615
tumors (2600) 2600
shareholder meetings (2551) 2551
hospitalization (2544) 2544
immune system (2466) 2466
health care (2455) 2455
financial performance (2452) 2452
diabetes (2436) 2436
pneumonia (2320) 2320
life sciences (2313) 2313
plasma (2261) 2261
viral infections (2214) 2214
immunology (2204) 2204
middle aged (2195) 2195
physicians (2173) 2173
pediatrics (2171) 2171
boards of directors (2130) 2130
coronavirus infections - drug therapy (2130) 2130
health aspects (2101) 2101
biological products (2094) 2094
gene therapy (2090) 2090
ventilators (2083) 2083
pneumonia, viral - epidemiology (2047) 2047
coronavirus infections - epidemiology (2033) 2033
dividends (2026) 2026
pneumonia, viral - drug therapy (2013) 2013
inflammation (1945) 1945
studies (1940) 1940
candidates (1881) 1881
metastasis (1881) 1881
chemotherapy (1772) 1772
aged (1767) 1767
medical equipment (1751) 1751
employees (1724) 1724
viral diseases (1709) 1709
adult (1687) 1687
antigens (1641) 1641
respiratory diseases (1641) 1641
trump, donald j (1640) 1640
breast cancer (1622) 1622
mutation (1604) 1604
research (1593) 1593
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (88024) 88024
Spanish (98) 98
Chinese (56) 56
French (54) 54
German (34) 34
Portuguese (33) 33
Russian (30) 30
Italian (20) 20
Hindi (11) 11
Japanese (7) 7
Norwegian (7) 7
Dutch (5) 5
Hungarian (5) 5
Urdu (5) 5
Danish (2) 2
Indonesian (2) 2
Swedish (2) 2
Turkish (2) 2
Hebrew (1) 1
Icelandic (1) 1
Korean (1) 1
Persian (1) 1
Polish (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature reviews. Drug discovery, ISSN 1474-1776, 03/2020, Volume 19, Issue 3, pp. 149 - 150
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Betacoronavirus - pathogenicity | Recombinant Proteins - therapeutic use | Interferon-alpha - pharmacology | Alanine - therapeutic use | Hepatitis C - drug therapy | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Polyethylene Glycols - therapeutic use | COVID-19 | Alanine - analogs & derivatives | Protease Inhibitors - pharmacology | SARS-CoV-2 | SARS Virus - genetics | Nucleosides - pharmacology | Spike Glycoprotein, Coronavirus - drug effects | Influenza, Human - drug therapy | Protease Inhibitors - therapeutic use | Polyethylene Glycols - pharmacology | Nucleosides - therapeutic use | Antiviral Agents - therapeutic use | Betacoronavirus - drug effects | Interferon-alpha - therapeutic use | Middle East Respiratory Syndrome Coronavirus - drug effects | SARS Virus - drug effects | Drug Repositioning | Recombinant Proteins - pharmacology | Adenosine Monophosphate - therapeutic use | SARS Virus - pathogenicity | Middle East Respiratory Syndrome Coronavirus - pathogenicity | Middle East Respiratory Syndrome Coronavirus - genetics | Adenosine Monophosphate - analogs & derivatives | Hepatitis B - drug therapy | HIV Infections - drug therapy | Betacoronavirus - genetics | Antiviral agents | Pharmacology, Experimental | Physiological aspects | Drug targeting | Genetic aspects | Research | Coronaviruses | Clinical trials | Index Medicus
Journal Article
Nature (London), ISSN 0028-0836, 07/2020, Volume 583, Issue 7816, pp. 469 - 472
Journal Article
Journal of medical virology, ISSN 0146-6615, 07/2020, Volume 92, Issue 7, pp. 797 - 806
northeast Chongqing | treatment | cognition | COVID‐19 | clinical features | Life Sciences & Biomedicine | Science & Technology | Virology | Betacoronavirus - pathogenicity | Diabetes Mellitus - pathology | Cough - physiopathology | Coronavirus Infections - drug therapy | Humans | Middle Aged | Pneumonia, Viral - drug therapy | Male | Tomography, X-Ray Computed | Interferons - therapeutic use | Neoplasms - diagnosis | Adrenal Cortex Hormones - therapeutic use | Fever - physiopathology | COVID-19 | Cardiovascular Diseases - complications | SARS-CoV-2 | Ritonavir - therapeutic use | Cardiovascular Diseases - diagnosis | Betacoronavirus - isolation & purification | Antiviral Agents - therapeutic use | Diabetes Mellitus - drug therapy | Diabetes Complications - drug therapy | Fatigue - diagnosis | Biomarkers - blood | Diabetes Complications - blood | Fever - virology | Neoplasms - drug therapy | Adolescent | Coronavirus Infections - pathology | Fatigue - physiopathology | Fatigue - virology | Pneumonia, Viral - diagnosis | Pandemics | COVID-19 Testing | Cardiovascular Diseases - drug therapy | Cough - diagnosis | Cardiovascular Diseases - pathology | Anti-Bacterial Agents - therapeutic use | Neoplasms - complications | China | Pneumonia, Viral - complications | Coronavirus Infections - complications | Adult | Female | Retrospective Studies | Diabetes Mellitus - diagnosis | Drugs, Chinese Herbal - therapeutic use | Severity of Illness Index | Cough - virology | Coronavirus Infections - diagnosis | Pneumonia, Viral - pathology | Fever - diagnosis | Clinical Laboratory Techniques - methods | Lopinavir - therapeutic use | Aged | Neoplasms - pathology | Drug Combinations | Corticoids | Therapy | Anorexia | Health services | Viral diseases | Malignancy | Gender | Epidemiology | Antiinfectives and antibacterials | Chinese medicine | Dyspnea | Computed tomography | Lymphocytes | Opacity | Public health | Hypertension | Signs and symptoms | Corticosteroids | Complications | Diabetes mellitus | Health risks | Traditional Chinese medicine | Fatigue | Lactate dehydrogenase | Myalgia | Coronaviruses | Patients | Fever | Cough | L-Lactate dehydrogenase | Herbal medicine | Infectious diseases | Respiratory distress syndrome | Cell number | Secondary infection | Interferon | Aspartate aminotransferase | Plasma levels | Dimers | Lactic acid | Cardiovascular diseases | Respiration | Index Medicus
Journal Article
Journal of medical virology, ISSN 0146-6615, 06/2020, Volume 92, Issue 6, pp. 556 - 563
coronavirus | SARS | COVID‐19 | lopinavir | MERS | Life Sciences & Biomedicine | Science & Technology | Virology | Betacoronavirus - pathogenicity | Severe Acute Respiratory Syndrome - epidemiology | Pandemics | Severe Acute Respiratory Syndrome - virology | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Betacoronavirus - enzymology | Severe Acute Respiratory Syndrome - diagnosis | COVID-19 | SARS-CoV-2 | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Middle East Respiratory Syndrome Coronavirus - enzymology | Ritonavir - therapeutic use | Disease Models, Animal | Cell Line | Antiviral Agents - therapeutic use | Coronavirus Infections - diagnosis | Betacoronavirus - drug effects | Middle East Respiratory Syndrome Coronavirus - drug effects | SARS Virus - drug effects | Treatment Outcome | Clinical Trials as Topic | Severe Acute Respiratory Syndrome - drug therapy | SARS Virus - pathogenicity | Middle East Respiratory Syndrome Coronavirus - pathogenicity | Animals | Coronavirus Infections - virology | Pneumonia, Viral - diagnosis | Lopinavir - therapeutic use | Mice | Pneumonia, Viral - virology | SARS Virus - enzymology | Epidemics | Health services | Therapeutic applications | Severe acute respiratory syndrome | Medical treatment | Lopinavir | Viral diseases | Health risks | Coronaviruses | Middle East respiratory syndrome | Literature reviews | Respiratory diseases | Public health | Index Medicus | Reviews | Review
Journal Article
by Gordon, David E and Jang, Gwendolyn M and Bouhaddou, Mehdi and Xu, Jiewei and White, Kris M and O’Meara, Matthew J and Rezelj, Veronica V and Swaney, Danielle L and Tummino, Tia A and Foussard, Helene and Batra, Jyoti and Haas, Kelsey and Modak, Maya and Kim, Minkyu and Braberg, Hannes and Fabius, Jacqueline M and Eckhardt, Manon and Soucheray, Margaret and Cakir, Merve and McGregor, Michael J and Li, Qiongyu and Vallet, Thomas and Mac Kain, Alice and Miorin, Lisa and Moreno, Elena and Zhou, Yuan and Peng, Shiming and Shi, Ying and Zhang, Ziyang and Shen, Wenqi and Melnyk, James E and Chorba, John S and Lou, Kevin and Dai, Shizhong A and Barrio-Hernandez, Inigo and Lyu, Jiankun and Mathy, Christopher J. P and Perica, Tina and Pilla, Kala Bharath and Ganesan, Sai J and Saltzberg, Daniel J and Rakesh, Ramachandran and Liu, Xi and Rosenthal, Sara B and Calviello, Lorenzo and Lin, Yizhu and Huang, Xi-Ping and Liu, YongFeng and Bohn, Markus and Safari, Maliheh and Ugur, Fatima S and Koh, Cassandra and Savar, Nastaran Sadat and Tran, Quang Dinh and Fletcher, Sabrina J and O’Neal, Michael C and Chang, Jason C. J and Broadhurst, David J and Klippsten, Saker and Sharp, Phillip P and Wenzell, Nicole A and Kuzuoglu-Ozturk, Duygu and Wang, Hao-Yuan and Trenker, Raphael and Young, Janet M and Cavero, Devin A and Hiatt, Joseph and Roth, Theodore L and Rathore, Ujjwal and Subramanian, Advait and Noack, Julia and Hubert, Mathieu and Stroud, Robert M and Frankel, Alan D and Rosenberg, Oren S and Verba, Kliment A and Agard, David A and Ott, Melanie and Emerman, Michael and Jura, Natalia and von Zastrow, Mark and Verdin, Eric and Ashworth, Alan and Schwartz, Olivier and d’Enfert, Christophe and Mukherjee, Shaeri and Jacobson, Matt and Malik, Harmit S and Craik, Charles S and Floor, Stephen N and Fraser, James S and Gross, John D and Roth, Bryan L and Ruggero, Davide and Taunton, Jack and Beltrao, Pedro and García-Sastre, Adolfo and Shokat, Kevan M and Shoichet, Brian K and Krogan, Nevan J
Nature (London), ISSN 0028-0836, 07/2020, Volume 583, Issue 7816, pp. 459 - 468
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Betacoronavirus - pathogenicity | Pandemics | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Host-Pathogen Interactions - drug effects | Molecular Targeted Therapy | Viral Proteins - metabolism | Protein Interaction Maps | COVID-19 | Pneumonia, Viral - metabolism | SARS-CoV-2 | Antiviral Agents - classification | Coronavirus Infections - metabolism | Mass Spectrometry | Cloning, Molecular | HEK293 Cells | Protein Domains | Drug Evaluation, Preclinical | Receptors, sigma - metabolism | Vero Cells | Antiviral Agents - pharmacology | Chlorocebus aethiops | Betacoronavirus - drug effects | Viral Proteins - genetics | SKP Cullin F-Box Protein Ligases - metabolism | Drug Repositioning | Betacoronavirus - metabolism | Immunity, Innate | Coronavirus Infections - immunology | Pneumonia, Viral - immunology | Protein Interaction Mapping | Animals | Coronavirus Infections - virology | Protein Binding | Protein Biosynthesis - drug effects | Betacoronavirus - genetics | Pneumonia, Viral - virology | Protein research | Drug targeting | Genetic aspects | Coronaviruses | Research | Health aspects | Methods | Interactomes | Drugs | Regulators | Laboratories | Protein purification | Viral diseases | Clinical trials | Infections | Genomes | mRNA | Vaccines | Middle East respiratory syndrome | Proteins | Antiviral activity | Antiviral agents | Enzymes | Severe acute respiratory syndrome | Cloning | Mass spectroscopy | RNA polymerase | Gene expression | Severe acute respiratory syndrome coronavirus 2 | Respiratory diseases | Fatalities | Scientific imaging | Protein interaction | Mass spectrometry | Index Medicus
Journal Article
BioFactors (Oxford), ISSN 0951-6433, 01/2021, Volume 47, Issue 1, pp. 6 - 18
acute respiratory distress syndrome | COVID‐19 | lung injury | specialized proresolving mediators | inflammation resolution | COVID-19 | Biochemistry & Molecular Biology | Endocrinology & Metabolism | Life Sciences & Biomedicine | Science & Technology | Lung Injury - pathology | Tuberculosis, Pulmonary - metabolism | Influenza, Human - pathology | Humans | Pulmonary Disease, Chronic Obstructive - virology | Tuberculosis, Pulmonary - drug therapy | Pulmonary Disease, Chronic Obstructive - pathology | Herpes Simplex - drug therapy | Periodontitis - metabolism | Sepsis - drug therapy | Lung Injury - virology | Respiratory Distress Syndrome - virology | Sepsis - pathology | COVID-19 - metabolism | Lipoxins - therapeutic use | Sepsis - metabolism | Lung Injury - metabolism | Anti-Inflammatory Agents - therapeutic use | Respiratory Distress Syndrome - drug therapy | Lung - metabolism | Influenza, Human - drug therapy | Lung Injury - drug therapy | Pulmonary Disease, Chronic Obstructive - metabolism | Docosahexaenoic Acids - therapeutic use | COVID-19 - virology | Influenza, Human - metabolism | Lung - pathology | Periodontitis - pathology | Tuberculosis, Pulmonary - pathology | COVID-19 - drug therapy | Herpes Simplex - metabolism | Respiratory Distress Syndrome - pathology | Periodontitis - drug therapy | SARS-CoV-2 - pathogenicity | Herpes Simplex - pathology | Lung - drug effects | Respiratory Distress Syndrome - metabolism | COVID-19 - pathology | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus
Journal Article